Four separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

BPC-157 + TB-500 + CJC-1295 + ipamorelin

BPC-157 + TB-500 + CJC-1295 + Ipamorelin

BPC-157 + TB-500 + CJC-1295 + ipamorelin: ingredient studies, complete-combination evidence gaps, dose, route and safety questions in the available research.

Peptide stack
Primary investigators

Recorded source check: 4 October 2026

Review and updates

Overview

This guide covers BPC-157 + TB-500 + CJC-1295 + Ipamorelin as a proposed combination. No primary study record of the complete combination is currently attached to this page, so the material here cannot establish an added benefit, a validated combined regimen, or a reliable rate of adverse events. Ingredient studies remain useful background, but they answer narrower questions about the intervention each paper actually tested. The gap described here concerns this guide’s linked sources and is not a claim that the combination has never been studied elsewhere.

Ingredients

  • BPC-157Read the ingredient evidence and its limits.
  • TB-500Read the ingredient evidence and its limits.
  • CJC-1295Read the ingredient evidence and its limits.
  • IpamorelinRead the ingredient evidence and its limits.

The combination examined on this page contains BPC-157 + TB-500 + CJC-1295 + Ipamorelin. Each ingredient needs to be identified by its actual molecule and preparation before research can be matched to the combination. The linked ingredient guides provide a route into that evidence, while ingredients without a dedicated guide remain named explicitly. A shared nickname, similar product label, or premixed presentation cannot establish that every ingredient, concentration, and route matches a published intervention.

Why combine them?

The reason to investigate BPC-157 + TB-500 + CJC-1295 + Ipamorelin together must be separated from evidence that the combination improves an outcome. A plausible role for each ingredient can motivate a study, but it does not show whether their effects complement one another, overlap, or introduce additional problems. The sources attached to this guide do not resolve that comparison for the complete stack. A convincing test would compare the proposed combination with the relevant individual ingredients and measure both the intended benefit and adverse events.

Combination benefits

No effectiveness assessment for the complete BPC-157 + TB-500 + CJC-1295 + Ipamorelin combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Safety & interactions

This page does not establish the safety or interaction profile of BPC-157 + TB-500 + CJC-1295 + Ipamorelin taken together. Assessing that question requires the full formulation, route, exposure, concurrent treatments, and adverse-event reporting from relevant combination research. Tolerability observed with an ingredient alone cannot establish the safety of adding the other ingredients, and missing reports cannot be treated as reassurance. Any proposed clinical use also requires an assessment of the individual’s circumstances rather than a conclusion drawn solely from a stack name.

Read the Medical Disclaimer.

Forms & dosing

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete BPC-157 + TB-500 + CJC-1295 + Ipamorelin combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Complete-combination evidence has not yet been assessed for this guide.

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

IngredientPDF recordAntiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy
IngredientPDF recordBPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
IngredientPDF recordBPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats
IngredientPDF recordBypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordCelecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
IngredientPDF recordClopidogrel-Induced Gastric Injury in Rats is Attenuated by Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordComplex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
IngredientPDF recordCounteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
IngredientPDF recordEffect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
IngredientPDF recordEffects of BPC-157 and TB-500 on Achilles tendon healing
IngredientPDF recordEffects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short- Bowel Rats
IngredientPDF recordEndothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
IngredientPDF recordEsophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
IngredientPDF recordFourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157
IngredientPDF recordImpact of pentadecapeptide BPC 157 on muscle healing
IngredientPDF recordIn relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
IngredientPDF recordIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
IngredientPDF recordIntragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
IngredientPDF recordModulatory effects of BPC 157 on vasomotor tone and the activation of Src‑Caveolin‑1‑endothelial nitric oxide synthase pathway
IngredientPDF recordNovel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
IngredientPDF recordOccluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordOcclusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension
IngredientPDF recordOver-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157
IngredientPDF recordPentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine
IngredientPDF recordPentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
IngredientPDF recordPentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion
IngredientPDF recordPentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
IngredientPDF recordPharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
IngredientPDF recordProtective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury
IngredientPDF recordProtective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
IngredientPDF recordProtective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
IngredientPDF recordRobert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
IngredientPDF recordSafety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
IngredientPDF recordSalutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
IngredientPDF recordStable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
IngredientPDF recordStable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS
IngredientPDF recordStable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
IngredientPDF recordStable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights
IngredientPDF recordThe anti-nociceptive effect of BPC-157 on the incisional pain model in rats
IngredientPDF recordThe effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
IngredientPDF recordTherapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats
IngredientPDF recordTracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats
IngredientPDF record0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
IngredientPDF recordA first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
IngredientPDF recordAssociation of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study
IngredientPDF recordEctopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice
IngredientPDF recordExpression and localisation of thymosin beta- 4 in the developing human early fetal heart
IngredientPDF recordGlobal Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma
IngredientPDF recordHypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
IngredientPDF recordHypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4
IngredientPDF recordIdentifi cation of Thymosin β 4 as an effector of Hand1-mediated vascular development
IngredientPDF recordLocal Photorelease of Caged Thymosin β4 in Locomoting Keratocytes Causes Cell Turning
IngredientPDF recordModulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: Possible implication in the regulation of actin dynamics
IngredientPDF recordPEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
IngredientPDF recordRGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
IngredientPDF recordRecombinant Human Thymosin β4 Attenuates Endotoxemia-Induced ALI and EAE by Suppressing Inflammatory and Oxidative Responses
IngredientPDF recordRecombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease
IngredientPDF recordRecombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
IngredientPDF recordRecombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
IngredientPDF recordRecombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
IngredientPDF recordReparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function
IngredientPDF recordSerum thymosin β4 levels in patients with hepatitis B virusrelated liver failure
IngredientPDF recordSignificance of Thymosin β4 and Implication of PINCH-1-ILK-α-Parvin (PIP) Complex in Human Dilated Cardiomyopathy
IngredientPDF recordStructural basis of actin sequestration by thymosin-β4: implications for WH2 proteins
IngredientPDF recordSynthesis of thymosin β4 by peritoneal macrophages and adherent spleen cells
IngredientPDF recordThe Control of Actin Nucleotide Exchange by Thymosin β4 and Profilin. A Potential Regulatory Mechanism for Actin Polymerization in Cells
IngredientPDF recordThymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
IngredientPDF recordThymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
IngredientPDF recordThymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice
IngredientPDF recordThymosin β4 Regulates Focal Adhesion Formation in Human Melanoma Cells and Affects Their Migration and Invasion
IngredientPDF recordThymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
IngredientPDF recordThymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell–derived cardiomyocytes in a porcine model of acute myocardial infarction
IngredientPDF recordThymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells
IngredientPDF recordThymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction
IngredientPDF recordThymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF- κB signaling axis in APP/PS1 mice
IngredientPDF recordThymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing
IngredientPDF recordThymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells
IngredientPDF recordThymosin-β4 Regulates Motility and Metastasis of Malignant Mouse Fibrosarcoma Cells
IngredientPDF recordThymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells
IngredientPDF recordThymosin β4: A ubiquitous peptide in rat and mouse tissues
IngredientPDF recordThymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
IngredientPDF recordThymosin beta‑4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells
IngredientPDF recordThymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
IngredientPDF recordThymosin β4 Sequesters the Majority of G-actin in Resting Human Polymorphonuclear Leukocytes
IngredientPDF recordNeuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth
IngredientPDF recordProbing for peptidic drugs (2–10 kDa) in doping control blood samples
IngredientPDF recordQualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
IngredientPDF recordAttenuation of Visceral and Somatic Nociception by Ghrelin Mimetics
IngredientPDF recordEfficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
IngredientPDF recordGrowth Hormone (GH) Hypersecretion and GH Receptor Resistance in Streptozotocin Diabetic Mice in Response to a GH Secretagogue

FAQs

Do the ingredient studies prove that the complete stack works?
Quick answer:

No effectiveness assessment for the complete BPC-157 + TB-500 + CJC-1295 + Ipamorelin combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Can separate study doses be combined into a stack protocol?
Quick answer:

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete BPC-157 + TB-500 + CJC-1295 + Ipamorelin combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for BPC-157 + TB-500 + CJC-1295 + ipamorelin.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.